全文获取类型
收费全文 | 2514篇 |
免费 | 146篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 89篇 |
妇产科学 | 64篇 |
基础医学 | 398篇 |
口腔科学 | 35篇 |
临床医学 | 194篇 |
内科学 | 626篇 |
皮肤病学 | 52篇 |
神经病学 | 310篇 |
特种医学 | 54篇 |
外科学 | 200篇 |
综合类 | 13篇 |
一般理论 | 1篇 |
预防医学 | 121篇 |
眼科学 | 17篇 |
药学 | 188篇 |
中国医学 | 6篇 |
肿瘤学 | 299篇 |
出版年
2023年 | 24篇 |
2022年 | 16篇 |
2021年 | 76篇 |
2020年 | 54篇 |
2019年 | 47篇 |
2018年 | 80篇 |
2017年 | 62篇 |
2016年 | 51篇 |
2015年 | 84篇 |
2014年 | 90篇 |
2013年 | 137篇 |
2012年 | 213篇 |
2011年 | 199篇 |
2010年 | 107篇 |
2009年 | 101篇 |
2008年 | 179篇 |
2007年 | 225篇 |
2006年 | 182篇 |
2005年 | 158篇 |
2004年 | 166篇 |
2003年 | 134篇 |
2002年 | 111篇 |
2001年 | 24篇 |
2000年 | 9篇 |
1999年 | 14篇 |
1998年 | 17篇 |
1997年 | 10篇 |
1996年 | 17篇 |
1995年 | 15篇 |
1994年 | 10篇 |
1993年 | 4篇 |
1992年 | 6篇 |
1991年 | 13篇 |
1990年 | 4篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1987年 | 9篇 |
1986年 | 3篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1977年 | 1篇 |
1975年 | 1篇 |
1973年 | 1篇 |
1971年 | 2篇 |
1970年 | 1篇 |
1969年 | 2篇 |
排序方式: 共有2673条查询结果,搜索用时 15 毫秒
1.
Nicla La Verde Agostino Riva Maria Silvia Cona Arianna Gabrieli Monica Cattaneo Cinzia Fasola Giuseppe Lipari Claudia De Stradis Valentina Favorito Benedetta Lombardi Stocchetti Davide Chizzoniti Alice Covizzi Eliana Rulli Francesca Galli Lorenzo Ruggieri Anna Gambaro Sabrina Ferrario Davide Dalu Maciej S. Tarkowski 《International journal of cancer. Journal international du cancer》2023,152(4):661-671
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single-institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA-1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS-CoV-2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty-one cancer patients had a previous exposure to SARS-CoV-2. Cancer patients previously exposed to the virus had significantly higher median levels of anti-S1 and anti-RBD IgG, compared to healthy controls (P = .0349) and to cancer patients without a previous infection (P < .001). Vaccine type (anti-S1: P < .0001; anti-RBD: P = .0045), comorbidities (anti-S1: P = .0274; anti-RBD: P = .0048) and the use of G-CSF (anti-S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS-CoV-2 significantly enhanced the response to vaccination (anti-S1: P < .0001; anti-RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS-CoV-2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination. 相似文献
2.
3.
4.
Stefanie Linder Simone B. Duss Charles Dvok Christoph Merlo Stefan Essig Kali Tal Cinzia Del Giovane Lamprini Syrogiannouli Raphael Heinzer Christoph Nissen Claudio L. A. Bassetti Reto Auer Micheline Maire 《Journal of sleep research》2021,30(1):e13169
Guidelines recommend cognitive behavioural therapy for insomnia (CBT‐I) as first‐line treatment for chronic insomnia, but it is not clear how many primary care physicians (PCPs) in Switzerland prescribe this treatment. We created a survey that asked PCPs how they would treat chronic insomnia and how much they knew about CBT‐I. The survey included two case vignettes that described patients with chronic insomnia, one with and one without comorbid depression. PCPs also answered general questions about treating chronic insomnia and about CBT‐I and CBT‐I providers. Of the 820 Swiss PCPs we invited, 395 (48%) completed the survey (mean age 54 years; 70% male); 87% of PCPs prescribed sleep hygiene and 65% phytopharmaceuticals for the patient who had only chronic insomnia; 95% prescribed antidepressants for the patient who had comorbid depression. In each case, 20% of PCPs prescribed benzodiazepines or benzodiazepine receptor agonists, 8% prescribed CBT‐I, 68% said they knew little about CBT‐I, and 78% did not know a CBT‐I provider. In the clinical case vignettes, most PCPs treated chronic insomnia with phytopharmaceuticals and sleep hygiene despite their lack of efficacy, but PCPs rarely prescribed CBT‐I, felt they knew little about it, and usually knew no CBT‐I providers. PCPs need more information about the benefits of CBT‐I and local CBT‐I providers and dedicated initiatives to implement CBT‐I in order to reduce the number of patients who are prescribed ineffective or potentially harmful medications. 相似文献
5.
Cinzia Maria Chinnici Giovanna Russelli Matteo Bulati Vitale Miceli Alessia Gallo Rosalia Bus Rosaria Tinnirello Pier Giulio Conaldi Gioacchin Iannolo 《World journal of gastroenterology : WJG》2021,27(17):1905-1919
Due to their immunomodulatory potential and release of trophic factors that promote healing, mesenchymal stromal cells (MSCs) are considered important players in tissue homeostasis and regeneration. MSCs have been widely used in clinical trials to treat multiple conditions associated with inflammation and tissue damage. Recent evidence suggests that most of the MSC therapeutic effects are derived from their secretome, including the extracellular vesicles, representing a promising approach in regenerative medicine application to treat organ failure as a result of inflammation/fibrosis. The recent outbreak of respiratory syndrome coronavirus, caused by the newly identified agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has forced scientists worldwide to use all available instruments to fight the infection, including the inflammatory cascade caused by this pandemic disease. The use of MSCs is a valid approach to combat organ inflammation in different compartments. In addition to the lungs, which are considered the main inflammatory target for this virus, other organs are compromised by the infection. In particular, the liver is involved in the inflammatory response to SARS-CoV-2 infection, which causes organ failure, leading to death in coronavirus disease 2019 (COVID-19) patients. We herein summarize the current implications derived from the use of MSCs and their soluble derivatives in COVID-19 treatment, and emphasize the potential of MSC-based therapy in this clinical setting. 相似文献
6.
7.
Giorgio Rizzo Marco Lo Presti Cinzia Giannini Teresa Sibillano Antonella Milella Giusy Matzeu Roberta Musio Fiorenzo G. Omenetto Gianluca M. Farinola 《Macromolecular chemistry and physics.》2020,221(13)
Silk fibroin (SF) obtained from Bombyx mori cocoon is a very promising biopolymer. It can be processed from aqueous solutions to obtain many versatile scaffolds useful in optoelectronics, photonics, and biomedicine. Aqueous solutions are prepared by dissolving degummed fibroin with chaotropic agents and then purifying by dialysis. This work presents, for the first time, a solubilization protocol, involving CeCl3·7H2O as chaotropic salt in water and ethanol, that allows to regenerate SF under a fibrous form, unlike the standard Ajisawa’s method, which uses CaCl2 and allows to obtain aqueous gels. All the experimental analyses performed (SEM, XPS, WAXS, ATR‐FTIR, NMR) suggest that the fiber recovered preserves most of the morphological and structural features of the pristine SF and is doped with Ce(III) ions, that interact mainly with the oxygen atoms of C?O moieties and side‐chains of amino acids. Ce(III) doped SF could be the base for new luminescent materials. 相似文献
8.
9.
10.